Orforglipron for Obesity
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new treatment called orforglipron, a medication for individuals with obesity or those who are overweight, with or without type 2 diabetes. The goal is to compare orforglipron to a placebo, a pill with no active ingredients, to evaluate its effectiveness and safety. Participants will be divided into groups to receive different doses of the treatment or a placebo. This trial may suit those who struggle with obesity or being overweight and frequently face weight-related issues, such as difficulty with physical activities. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants a chance to contribute to a potentially groundbreaking treatment.
Do I need to stop my current medications for the Orforglipron trial?
The trial information does not specify if you need to stop your current medications. It's best to check the specific study criteria for more details.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research has shown that orforglipron is generally safe for people with obesity. Studies testing various doses, including 6 mg, 12 mg, and 36 mg, have demonstrated significant weight loss compared to a placebo. Side effects were similar to those of other treatments in the same category, suggesting that most people can use orforglipron without serious issues. The trial's late stage indicates that earlier research found the treatment to be relatively safe.12345
Why do researchers think this study treatment might be promising for obesity?
Orforglipron is unique because it offers a promising new approach to managing obesity. Unlike typical treatments that may involve invasive procedures or injections, Orforglipron is taken orally, making it more convenient for patients. Most current obesity treatments focus on reducing appetite or altering fat absorption, but Orforglipron works differently by targeting specific pathways in the body to help regulate metabolism more effectively. Researchers are excited about its potential to provide significant weight loss with fewer side effects and increased ease of use compared to existing options.
What evidence suggests that orforglipron might be an effective treatment for obesity?
Research has shown that orforglipron helps people lose weight. In one study, participants taking orforglipron lost between 7.8% and 12.4% of their starting weight over 72 weeks, with 73.1% of this reduction being fat mass. Another study found that people lost up to 16 pounds on the highest dose. Overall, orforglipron led to significantly more weight loss than a placebo (a pill with no active ingredients). These results suggest orforglipron could be a promising option for managing obesity. Participants in this trial will receive different doses of orforglipron or a placebo to further evaluate its effectiveness.12467
Who Is on the Research Team?
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
Principal Investigator
Eli Lilly and Company
Are You a Good Fit for This Trial?
This clinical trial is open to individuals who are overweight or obese, with some participants also having type 2 diabetes. There aren't specific eligibility criteria for the master protocol, meaning a broad range of people could potentially participate.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive orforglipron or placebo orally
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Orforglipron
Find a Clinic Near You
Who Is Running the Clinical Trial?
Eli Lilly and Company
Lead Sponsor
Dr. Daniel Skovronsky
Eli Lilly and Company
Chief Medical Officer since 2018
MD from Harvard Medical School
David A. Ricks
Eli Lilly and Company
Chief Executive Officer since 2017
BSc from Purdue University, MBA from Indiana University